Table III.

Recent clinical trials targeting the inflammasome

Drug name	Inflammasome target	Disorder	Study type	Results	Source
DFV890	NLRP3	COVID-19	Clinical Trial	Reduced COVID pathology	128
				Reduced ventilator intervention
MAS825	NLRC4	COVID-19	Clinical Trial	Decreased C-reactive protein	129
				No change in clinical outcomes
OLT1177	NLRP3	Heart Failure	Clinical Trial	Improved left ventricular ejection fraction	130
Dapansutrile		Gout	Clinical Trial	Reduced joint pain	131
IZD334	NLRP3	Autoinflammatory Disease	Clinical Trial	Trial complete	132
Inzomelid	NLRP3	Autoinflammatory Disease	Clinical Trial	Trial complete	132
MCC950	NLRP3	AD	Animal Study	Increased Aβ phagocytosis	125
		TBI	Animal Study	Reduced caspase-1 and IL-1β activity	125
		Rheumatoid Arthritis	Clinical Trial	Severe side effects	125,133
VX765	Caspase-1	TBI	Animal Study	Reduced cytokine and GSDM-D activity	127
		Alzheimer’s Disease	Animal Study	Delayed inflammatory onset	126
				No change in plaque load
IC-100	ASC	Aging	Animal Study	Reduced Caspase-1,8, Il-1β, ASC, NLRP-1 expression	22
		Multiple Sclerosis	Animal Study	Reduced T cell, myeloid cell, and microglia activation	123
		CNS induced Lung Injury	Animal Study	Reduced Il-1β, ASC, caspase-1, AIM2 expression	6
				Reduced lung tissue damage
		TBI	Animal Study	Reduced caspase-1 and pyroptosis	11

The inflammasome represents a promising target in the treatment of numerous inflammatory fueled pathologies. Current clinical studies have shown that therapeutics that target inhibition of the inflammasome sensor are safe, well tolerated, and potentially effective in numerous inflammatory pathologies.